Navigation Links
Saliva Test Could Monitor Type 2 Diabetes
Date:1/20/2009

Test might one day replace current blood tests, researchers say

TUESDAY, Jan. 20 (HealthDay News) -- Scientists say they are on the verge of developing a saliva test for monitoring type 2 diabetes, which might someday replace invasive blood tests.

For the first time, researchers from Oregon and India have identified proteins in saliva that appear more frequently in people with diabetes than in non-diabetics. Using these proteins, they are working to develop a test to monitor and perhaps diagnose the condition.

However, Dr. Umesh Masharani, an associate clinical professor of medicine at the University of California, San Francisco, doesn't think this approach is going to replace current blood tests any time soon.

"I think this is an interesting and novel approach," Masharani said. "I do not think this approach will be used in the diagnosis or treatment of diabetes any time in the near future. It is interesting, I think, for research studies in diabetes."

The report was published in the Jan. 2 issue of the Journal of Proteome Research.

For the study, Paturi V. Rao, from the departments of Endocrinology and Metabolism and Medicine at Nizam's Institute of Medical Sciences University in Hyderabad, India, and colleagues analyzed saliva samples from people with and without type 2 diabetes. Their goal was to find proteins associated with the blood sugar disease.

The researchers found 65 proteins that occurred twice as frequently in the people with diabetes than in those without the condition.

Using these proteins, Rao's team hopes to develop a noninvasive test for diabetes screening, detection and monitoring.

Rao's group thinks the pain involved with current diabetes monitoring causes many diabetics to be lax in monitoring their condition. A noninvasive test could make it easier and less painful for patients to keep track of their blood sugar levels.

"As recent studies have shown that early and multi-factorial intervention in diabetes prevents cardiovascular complications and mortality, advances in understanding molecular aspects of preclinical diabetes will further facilitate accurate diagnosis and early intervention," the authors wrote.

Diabetes expert Dr. Charles F. Burant, a professor of internal medicine at the University of Michigan, isn't convinced that a test using proteins in saliva is needed.

"I think it has minimal clinical impact," Burant said. "To be a valid biomarker, a test has to be sensitive and specific. We don't know the value of either for any of the proteins at the present time."

The biggest question is why this is needed, Burant noted. "Diabetes and prediabetes have a valid biomarker -- glucose -- that is the measure of the disease state. Thus, this is interesting biochemistry and raises questions why these changes occur, but the clinical utility is unclear."

More information

For more about type 2 diabetes, visit the American Diabetes Association.



SOURCES: Umesh Masharani, M.D., associate clinical professor, medicine, University of California, San Francisco; Charles F. Burant, M.D., Ph.D., professor, internal medicine, University of Michigan, Ann Arbor; Jan. 2, 2009, Journal of Proteome Research


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. UT Health Science Center researchers decoding saliva to detect breast cancer
2. Salivary diagnostics, the magic mirror to your health ... at your personal computer
3. Melvin receives Salivary Research Award
4. Bi-Coastal Pharmaceutical Corp. Acquires U.S. Marketing Rights to Aquoral(TM) Artificial Saliva Product
5. Bat Saliva-Based Stroke Drug Disappoints in Trial
6. Saliva Test Could Indicate Autism
7. Study provides hope that some transplant patients could live free of antirejection drugs
8. Study provides hope that some transplant patients could live free of anti-rejection drugs
9. HIV denialists spread misinformation online -- consequences could be deadly; and more
10. Virus Could Help Drive Obesity
11. Discovery of sugar sensor in intestine could benefit diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Saliva Test Could Monitor Type 2 Diabetes
(Date:2/27/2017)... ... February 27, 2017 , ... ... overview on laser diffraction analysis as a tool to characterize particle size distributions ... potential to obtain improved results and novel scientific findings. It describes methods of ...
(Date:2/27/2017)... , ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. ... has disclosed that despite scientific studies, the Center for Disease Control ( CDC ) ... disease . Kenneth B. Liegner, M.D. has compiled into a single volume a ...
(Date:2/27/2017)... BC (PRWEB) , ... February 27, 2017 , ... ... drug rehabilitation and alcohol treatment programs in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ ... to its team. The new hire, Mackenzie Alsager, showcases the Centre's commitment to ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... ... San Francisco and environs, is proud to announce an upgrade to the company's ... the upgraded Yelp page on topics as diverse as Platelet Rich Plasma (PRP) ...
(Date:2/26/2017)... ... February 25, 2017 , ... The February 13, 2017, assassination of Kim ... over nerve agents and the deadly use of chemical weapons. Many questions exist about ... even small doses can be lethal. , Jay Jagannathan, M.D., of Michigan-based Jagannathan Neurosurgical ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... , Feb. 27, 2017  A ... P. Vallely , MBBS, PhD, FRACS, of  Sydney ... University of Sydney will be published in ... of the American College of Cardiology ... beating heart bypass surgery technique (anOPCABG) reduced ...
(Date:2/27/2017)... Biophysics Corporation, a global medical device manufacturer based in ... growth in 2016 when compared to the previous year based ... fueled by its AffloVest® sales in the United ... global sales of surgical product lines. Said H. ... 25 th year in delivering high-quality, innovative medical devices ...
(Date:2/27/2017)... ROCKVILLE, Md. , Feb. 27, 2017 /PRNewswire/ ... "RegeneRx"), a clinical-stage drug development company focused on ... its licensee for RGN-137, GtreeBNT Co., Ltd., received ... its Phase 3 clinical trial design for RGN-137 ... dermal wound healing gel that incorporates Thymosin beta ...
Breaking Medicine Technology: